Sun Pharma-Organon deal: $11.75bn all-cash buyout

Deal announced from Mumbai and Jersey City

Sun Pharmaceutical Industries and Organon & Co. said they have signed a definitive merger agreement under which Sun Pharma will acquire all outstanding Organon shares for US$14.00 per share in cash. The transaction is structured as an all-cash deal and values Organon at an enterprise value of US$11.75 billion. The announcement was dated April 26, 2026 from Jersey City and April 27, 2026 from Mumbai, as reflected in an SEC 8-K filing referenced in the coverage. Both companies positioned the transaction as a portfolio and scale-driven combination.

What Sun Pharma is buying and why it matters

Sun Pharma said the acquisition aligns with its strategy of growing its Innovative Medicines business. It also aims to strengthen its position in Established Brands or branded generics, where Organon has a sizeable footprint. A key strategic element highlighted in the joint communication is Sun Pharma’s entry into biosimilars as a Top-10 global player. The companies said Organon’s portfolio, global footprint, and stakeholder relationships complement Sun Pharma’s existing strengths, with an emphasis on long-term value creation.

Transaction structure and funding plan

Sun Pharma will acquire 100% of Organon’s issued and outstanding shares for cash. The deal will be effected through a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger. Sun Pharma plans to fund the acquisition through a mix of available cash resources and committed financing from banks. The transaction has been approved by the boards of both Sun Pharma and Organon.

Closing conditions and expected timeline

The acquisition is subject to customary closing conditions, including required regulatory approvals and approval by Organon stockholders. Sun Pharma said it expects the transaction to close in early 2027, assuming these conditions are met. Organon also indicated it intends to file merger-related materials with the SEC, including a proxy statement on Schedule 14A.

Market reaction: Sun Pharma and Organon stocks jump

The announcement triggered a sharp move in both stocks. Sun Pharma’s BSE-listed shares rose more than 7%, hitting an intraday peak of ₹1,766.90 on April 27. Organon’s NYSE-listed stock jumped 17% the same day. Coverage also described Sun Pharma trading as much as 5% higher on April 27 following the definitive agreement.

Premiums, analyst targets, and the price paid

The US$14.00 offer price implies a 24% premium to Organon’s closing price on April 25, 2026. It also represents a 103% premium to the April 9 level cited as the last unaffected trading day before media reports of a possible deal surfaced (as referenced in an SEC DEFA14A filing). Separately, coverage cited five covering sell-side analysts having a consensus price target of US$10.40 as of April 27 (TIKR data), framing the offer as materially above Street expectations.

Scale of the deal in 2026 and in Indian pharma history

The transaction was described as the largest overseas pharmaceutical acquisition ever by an Indian company. It was also presented as the biggest biopharma transaction globally in 2026 so far, exceeding Eli Lilly’s US$1.8 billion buyout of Centessa Pharmaceuticals, as cited in the provided text.

What the companies said about integration priorities

Sun Pharma Managing Director Kirti Ganorkar said immediate priorities would be “business continuity, disciplined integration, and responsible value creation,” and also pointed to leveraging Organon’s talent pool and a scope for synergies, including revenue upside over the coming years. Organon Executive Chair Carrie Cox said the board’s review of strategic alternatives led it to conclude the all-cash transaction offers compelling and immediate value to stockholders, and that Sun Pharma is positioned to support Organon’s businesses, employees, and patients globally. Sun Pharma Executive Chairman Dilip Shanghvi said Organon’s portfolio, capabilities, and global reach are highly complementary to Sun Pharma’s.

Biosimilars and portfolio overlap highlighted in the coverage

One strategic shift emphasized is that Sun Pharma gains a functioning biosimilar business through Organon. The text cites Organon’s biosimilar business growing 23% in Q1 2026, and says the deal would make Sun Pharma the seventh-largest biosimilar player globally by revenue, per the joint statement referenced. The coverage also noted a portfolio link: Sun Pharma’s psoriasis drug Ilumya traces scientific roots to Organon’s labs, which was presented as an operational overlap that could help early integration.

Key numbers at a glance

Conclusion

Sun Pharma’s agreement to buy Organon for US$11.75 billion EV is a landmark outbound deal from India, combining established brands, women’s health exposure, and a ready biosimilars platform under one roof. The next milestones are procedural rather than commercial: SEC filings, Organon stockholder approval, and regulatory clearances, with both companies guiding to an early 2027 close.